Learn about peptide therapy and its potential role in supporting recovery, anti-aging, and overall wellness. Our content explores how peptides may help optimize cellular function and performance. Discover emerging research and medical applications for targeted health goals. Stay informed on innovative therapy options.
Quick answer: In 2023 the FDA placed 19 peptides on a restricted list that effectively stopped compounding pharmacies from preparing them. That began reversing in 2026. Twelve peptides came off the restricted list effective April 23, 2026, and the FDA’s Pharmacy Compounding Advisory Committee reviewed seven of them at its July 23–24, 2026 meeting. Coming…
Quick answer: The FDA’s Pharmacy Compounding Advisory Committee met July 23 and 24, 2026 and recommended six of seven peptides for the 503A Bulks List: BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon. Emideltide, also called DSIP, was rejected. Every vote was close, and the committee went against its own FDA staff’s written recommendation on all…